We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
4 own
7 watching
Current Price
$1.94
$-0.22
(-10.19%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
210.44M
52-Week High
9.34
52-Week Low
1.4188
Average Volume
0.12M
Dividend Yield
--
P/E Ratio
--
Market Capitalization210.44M
52-Week High9.34
52-Week Low1.4188
Average Volume0.12M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
18days ago
Evelo Biosciences, Inc. (NASDAQ:EVLO Get Rating) was the target of some unusual options trading activity on Wednesday. Traders acquired 1,885 put options on the company. This is an increase of approximately 1,101% compared to the average daily volume of 157 put options. Evelo Biosciences Stock ...
PR Newswire
1month ago
Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform PR Newswire CAMBRIDGE, Mass., Oct. 17, 2022 Dr. Khrer has more than 25 years of RNA research and development experience, including pioneering novel...
Globe Newswire
3 months ago
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today presented biomarker data demonstrating the broad anti-...
PR Newswire
3 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Evelo Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Evelo Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its...
Globe Newswire
4 months ago
CAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$1.94
$-0.22
(-10.19%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00